Effects of remote ischemic conditioning on blood pressure in older patients with hypertension

This study is testing whether a new non-invasive treatment can help lower blood pressure in older adults with high blood pressure.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 158 (estimated)
• Ages: 65 Years to 85 Years
• Sex: All
• Sponsor: The First Hospital of Jilin University (Academic / other)
• Locations: 1 site (Changchun, Jilin)
• Trial ID: NCT05845905 on ClinicalTrials.gov

What this trial studies

This study investigates the impact of remote ischemic conditioning on blood pressure levels in older adults suffering from essential hypertension. The approach involves applying a non-invasive technique that may enhance vascular function and reduce sympathetic nervous system activity, potentially leading to lower blood pressure. Participants will be randomly assigned to receive either the active treatment or a sham procedure to assess the effectiveness of the intervention. The study aims to provide insights into a novel method for managing hypertension in this age group.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 65 to 85 with a history of essential hypertension and a systolic blood pressure of 140 mmHg or higher.

Not a fit: Patients with secondary hypertension, severe organ dysfunction, or contraindications to remote ischemic conditioning may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could offer a new, non-invasive treatment option for managing high blood pressure in older patients.

How similar studies have performed: Previous studies have shown promising results with remote ischemic conditioning, suggesting potential benefits for blood pressure management, although this specific application in older patients is less explored.

Eligibility criteria

Inclusion Criteria:

* 1\) Age ≥65 years and ≤85 years, regardless of gender;
* 2\) History of essential hypertension and clinical systolic blood pressure ≥ 140 mmHg, regardless of whether they are receiving antihypertensive medication;
* 3\) Willing to participate and sign the informed consent.

Exclusion Criteria:

* 1\) Secondary hypertension;
* 2\) Clinical blood pressure ≥ 180/110 mmHg or 24-hour mean arterial pressure ≥ 170/100 mmHg;
* 3\) Severe organ dysfunction or failure;
* 4\) Severe hematologic disorders or significant coagulation abnormalities;
* 5\) History of atrial fibrillation or myocardial infarction within 6 months;
* 6\) Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
* 7\) Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc;
* 8\) Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment;
* 9\) Other conditions that the researchers think are not suitable for the project.

Where this trial is running

Changchun, Jilin

• First Hospital of Jilin University — Changchun, Jilin, China (Recruiting)

Study contacts

• Study coordinator: Yi Yang, MD, PhD

Conditions Essential Hypertension